Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Annual-Meeting

5 months
78 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Joseph Tabernero, MD, discusses the phase 3 keynote-062 study. Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined positive score ?1 (CPS ?1), HER2-negative, advanced GC. Methods: Eligible pts were randomized 1:1:1 to P 200 mg Q3W for up to 2 y, P+C (cisplatin 80 mg/m2 + 5-FU 800 mg/m2/d on d1-d5 Q3W [or capecitabine 1000 mg/m2 BID on d1-d14 Q3W per local guideline]) or placebo Q3W + C. Randomization was stratified by region, disease status, and fluoropyrimidine treatment. Primary endpoints were OS in CPS ?1 and CPS ?10 for P+C vs C and P vs C and PFS (RECIST v1.1; central review) in CPS ?1 for P+C vs C. ORR (RECIST v1.1; central review) in CPS ?1 for P+C vs C was the secondary endpoint. Final analysis cutoff date was 26 Mar 2019. Results: 763 pts (281 with CPS ?10) were randomized to P+C (257), P (256), or C (250) (Table). Median follow-up was 11.3 mo. P was noninferior to C for OS in CPS ?1 per prespecified margins. P vs C prolonged OS in CPS ?10 (median 17.4 vs 10.8 mo; HR 0.69; 95% CI 0.49-0.97) but wasnt tested per analysis plan. P+C vs C was not superior for OS in CPS ?1 or CPS ?10, with a favorable trend for P+C. P+C did not significantly prolong PFS in CPS ?1. ORR was higher for P+C vs C. Grade 3-5 drug-related AE rates were 17% (P), 73% (P+C), and 69% (C). Conclusions: As 1L therapy for advanced GC, P was noninferior to C for OS in CPS ?1 with clinically meaningful improvement for OS in CPS ?10. P+C did not show superior OS and PFS in CPS ?1 and OS in CPS ?10. The safety profile was more favorable for P vs C. Clinical trial information: NCT02494583
Up Next Autoplay
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Drug Resistance Found as Instestinal Tumor: How This Affects Clinicians
Category: Gastrointestinal Cancer
4 Views
Massachusetts General Hospital 2 weeks
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Cause of Drug Resistance Found in a Form of Intestinal Tumor
Category: Gastrointestinal Cancer
11 Views
Massachusetts General Hospital 2 weeks
Intestinal Tumor Commonly Asked Questions
Intestinal Tumor Commonly Asked Questions
Category: Gastrointestinal Cancer
4 Views
Massachusetts General Hospital 2 weeks
Drug Resistance Found As Intestinal Tumor
Drug Resistance Found As Intestinal Tumor
Category: Gastrointestinal Cancer
13 Views
Massachusetts General Hospital 2 weeks
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1  Positive Advanced Gastric Cancer
KEYNOTE-062: Pembrolizumab in HER2-, PD-L1 Positive Advanced Gastric Cancer
Category: Gastrointestinal Cancer
174 Views
obr 4 months
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
When Do You Prescribe Bland Vs Chemo Or Radio Embolization: Chemo Embolization Has Not Caught On In Our Institution Because The Side Effects & Extra Months Of Durability Are Not Of Value
Category: Gastrointestinal Cancer
217 Views
Annual-Meeting 5 months
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Inducing Embolization Syndrome When Performing infarction: Not Uncommon To Take 4-8 Weeks To Get Over The Treatment Of Embolotherapy
Category: Gastrointestinal Cancer
26 Views
Annual-Meeting 5 months
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Evaluating mTOR Inhibitor Everolimus With Embolotherapy: Objective Response Rate Of 57 We Did Not Stop Everolimus During Embolotherapy, We Continued It
Category: Gastrointestinal Cancer
126 Views
Annual-Meeting 5 months
Caring For Every Patient And Learning From Every Patient
Caring For Every Patient And Learning From Every Patient
Category: Gastrointestinal Cancer
159 Views
Annual-Meeting 5 months
The Quality and Completeness of Data
The Quality and Completeness of Data
Category: Gastrointestinal Cancer
114 Views
Annual-Meeting 5 months